Toward a cure for chronic lymphocytic leukemia: an attack on multiple fronts
Open Access
- 1 September 2013
- journal article
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 13 (9) , 1009-1012
Abstract
No abstract availableThis publication has 22 references indexed in Scilit:
- Vinblastine Rapidly Induces NOXA and Acutely Sensitizes Primary Chronic Lymphocytic Leukemia Cells to ABT-737Molecular Cancer Therapeutics, 2013
- Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivoLeukemia, 2013
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing plateletsNature Medicine, 2013
- The B-cell receptor signaling pathway as a therapeutic target in CLLBlood, 2012
- Design of novel BH3 mimetics for the treatment of chronic lymphocytic leukemiaLeukemia, 2012
- Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory DiseaseJournal of Clinical Oncology, 2012
- RETRACTED ARTICLE: MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complexLeukemia, 2011
- An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737Blood, 2011
- The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemiaBlood, 2011
- Chronic lymphocytic leukemia incidence is substantially higher than estimated from tumor registry dataCancer, 2001